Search research articles
Contact Us
Filters
Showing results (191-200 of 215) with videos related to
Page
of 22
Sort By:
World Journal of Urology
|
September 29, 2021
Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients
L M C van Hoogstraten, E J van Gennep, L A L M Kiemeney, et al.
European Urology
|
March 16, 2024
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31]
J Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
Contemporary Clinical Trials Communications
|
April 27, 2018
Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial
T van Doeveren, P J van Leeuwen, K K H Aben, et al.
BJU International
|
September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer
Michiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2025
Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial
Chantal F Stockem, Jeroen van Dorp, Nick van Dijk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 9, 2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Chantal F Stockem, Alberto Gil-Jimenez, Hamza Ali, et al.
European Urology Oncology
|
June 21, 2024
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels
Laura S Mertens, Harman Maxim Bruins, Roberto Contieri, et al.
Nature Medicine
|
July 17, 2023
Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Jeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann, et al.
American Journal of Human Genetics
|
November 25, 2010
Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia
Sascha Vermeer, Alexander Hoischen, Rowdy P P Meijer, et al.
Nature Medicine
|
February 27, 2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
Jan-Jaap J Mellema, Chantal F Stockem, Cameron Herberts, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 215) with videos related to
Sort By:
Page
of 22
World Journal of Urology
|
September 29, 2021
Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients
L M C van Hoogstraten, E J van Gennep, L A L M Kiemeney, et al.
European Urology
|
March 16, 2024
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31]
J Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
Contemporary Clinical Trials Communications
|
April 27, 2018
Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial
T van Doeveren, P J van Leeuwen, K K H Aben, et al.
BJU International
|
September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer
Michiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2025
Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial
Chantal F Stockem, Jeroen van Dorp, Nick van Dijk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 9, 2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Chantal F Stockem, Alberto Gil-Jimenez, Hamza Ali, et al.
European Urology Oncology
|
June 21, 2024
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels
Laura S Mertens, Harman Maxim Bruins, Roberto Contieri, et al.
Nature Medicine
|
July 17, 2023
Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Jeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann, et al.
American Journal of Human Genetics
|
November 25, 2010
Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia
Sascha Vermeer, Alexander Hoischen, Rowdy P P Meijer, et al.
Nature Medicine
|
February 27, 2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
Jan-Jaap J Mellema, Chantal F Stockem, Cameron Herberts, et al.
Page
of 22